

Inflammatory markers in MPOX and HIV Co-infection during the 2022-23 outbreak, Dominican Republic

Poster #: ectmih2023.15006b6

Robert Paulino-Ramirez, Hector Lora, & Leandro Tapia

1. Instituto de Medicina Tropical & Salud Global, Universidad Iberoamericana (UNIBE), Santo Domingo, Dominican Republic

Background

There is limited data to comprehend the clinical outcomes of MPOX (formerly monkeypox virus) infection in people living with HIV (PLWHIV), especially in low and middle- income (LMIC) countries during the 2022-23 outbreak. Previous studies have shown that immunocompromised status has been associated with a longer presentation and increasing the severity of the symptoms and mortality. This study is aimed to describe findings of co-infections in the DR.

Methods

An observational analysis of cases with PCR-confirmed MPOX infection attending an HIV/STI clinic in Santo Domingo. Samples were analyzed November 2022-January 2023. Participant data were collected from medical records during hospitalization and follow-up.

Results

- All participants were previously enrolled in HIV care and antiretroviral therapy, and self-identified as MSM with a mean age of 36.2 years. All developed systemic symptoms and skin lesions.
- Distribution of pustules was more frequent in the face (perioral) and genital/anal region, and the involvement of hands and feet was not reported. (Figure 1A/B)
- Fever and lymphadenopathies were reported in all cases. No other STIs were identified. Only one case required hospitalization and no fatalities were associated. Mean of effervescence manifestations was 24 days.
- HIV viral load showed no modifications before and after infection, however, CD4/CD8 ratio was observed before and after the infection (mean 2.6) (Table 1).
- Frequency of perioral lesions, and systemic manifestations were common among all cases.
- Geographical distribution of HIV(+)/(-) and MPOX (+)/(-) or UNK contacts was analyzed (Figure 2).

Conclusions

Pro-inflammatory reactions in MPOX infections observed in CD4:CD8 ratios might be of importance on outcomes and severity, and prolonged pustular stages. Public health actions to prevent mpox-HIV associated-deaths shall include integrated testing, diagnosis, and early treatment for mpox and HIV, and ensuring equitable access to both mpox and HIV prevention and treatment, such as antiretroviral therapy (ART).

Table 1. Clinical findings in MPOX/HIV co-infections in the Dominican Republic

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age (Mean 36.2; IQR 10)	32	35	49	32	33
HIV status	+	+	+	+	+
Fever	Y	Y	Y	Y	Y
Lymphadenopathies					
Cervical	Y	Y	Y	N	N
Inguinal	Y	Y	Y	Y	Y
Pustular lesions					
Head and neck	Y	Y	Y	Y	Y
Perioral	Y	Y	Y	Y	Y
Face	Y	Y	Y	Y	Y
Nasal	Y	Y	Y	Y	Y
Trunk	Y	N	Y	N	N
Abdomen	Y	N	Y	N	N
Genital lesions	Y	Y	Y	Y	Y
Perianal	Y	Y	Y	Y	Y
Penis/Scrotal	Y	Y	Y	Y	Y
Local Complications	N	N	N	N	N
Days with symptoms					
	16	19	29	26	30
Mean	24	IQR 12			
Median	26				
HIV viral load (copies/mm3)					
	< 1000	< 450	< 40	<40	<40
T lymphocyte count					
CD4 + count (µ/mL)	363	425	440	389	506
CD8 + count (µ/mL)	202	239	320	289	309
CD4:CD8 ratio (µ/mL)	1.8	1.7	1.4	1.3	1.6
Variability CD4:CD8 ratio after	1.9	2.0	1.9	1.9	2.6
MPOX infection					
Mean	2.6	IQR 0.4			
Median	1.9				




Figure 1A/B. Pustular lesions associated to MPOX infection in a PWH (day 8 after onset of symptoms.*




Figure 2. Geo-distribution of studied cases (four red dots (in the capital city, Santo Domingo) shared the same encounter site, a gay sauna. One red dot outlines in the south-west did not refered visiting any gay venue. Red depicts the five HIV positive cases described, and close contacts (approx. 5-15 days) before onset of MPOX symptoms. All contact nformation was provided by MPOX/HIV (+) participants.

